Feed ABCL
AB

AbCellera Biologics Inc. ABCL · NASDAQ

$11.80 -6.94% (-$0.88)

Market cap
$3.87B
Enterprise value
$3.89B
P/E
-
Forward P/E
-
PEG
-
P/S
58.5x
P/FCF
-
EV/EBITDA
-
ROIC
-15.0%
Gross margin
75.0%
Net margin
-248.8%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.19
Free float
64.5%

About the company

AbCellera Biologics Inc. (ABCL) is a biotechnology company specializing in the development of monoclonal antibodies and other biological therapeutics for the treatment of various diseases, including infectious diseases and cancer. The company utilizes advanced technologies such as artificial intelligence and wide-scale antibody scanning to identify and develop potentially effective therapies. AbCellera collaborates with pharmaceutical companies on drug development and therapeutic approaches. With its innovations in the field of biological therapeutics and partnerships with the pharmaceutical industry, investing in AbCellera Biologics Inc. (ABCL) shares may present an interesting investment opportunity for investors interested in the biotechnology and medical sectors.

Sector

Healthcare

Industry

Biotechnology

CEO

Carl Hansen

Employees

562

Headquarters

Vancouver

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.